Navigation Links
European-wide study confirms benefits of D-penicillamine and trientine for Wilson disease

Results from the first ever European-wide retrospective analysis presented today at the International Liver CongressTM have shown both D-penicillamine and trientine continue to be effective treatments, providing positive survival rates in patients with Wilson disease free from a liver transplant.

Wilson disease is a rare genetic storage disorder in which copper is not excreted by the body effectively, leading to excess copper build up, liver failure and damage to the brain (neurological problems). Worldwide the condition, affects approximately one in 30,000 people. If not treated, Wilson disease can be chronically debilitating and life threatening. While current guidelines recommend the use of chelating agents (D-penicillamine, trientine) as first line therapy of symptomatic patients, optimal treatment regimens are yet to be established.

In this retrospective multicentre cohort study the long-term outcomes of treatment with D-penicillamine and trientine were reviewed in 347 patients with the condition. Changes of medication were common in both groups and resulted in a total of 467 analysed treatments (D-penicillamine, n=326, trientine n=141). Following an average follow-up of 16.5 years, both treatments provided a similar and excellent survival rate and prevented disease progression with the need for liver transplantation in over 98% of patients.

Daniele Prati, EASL's Scientific Committee Member and Press Committee Chairman commented: "Not only does this study show that both treatments are effective options for patients with this rare and often debilitating condition, but it is also encouraging to see how European countries can work together and exchange data which is extremely valuable to guide best practice and evaluate existing treatment regimens. Research on rare liver diseases presents remarkable interest."

"To date, a very limited number of drugs for these conditions are marketed, leaving the majority of rare diseases without any effective treatment. Research into rare diseases and possible cures needs to be strongly encouraged."

Follow-up at 48 months showed that liver deterioration occurred in only 8 out of 515 treatments (D-penicillamine n=4, trientine n=4) while neurological deterioration was less frequent in the D-penicillamine group (7/326 treatments) compared to trientine (12/141, p≤=0.05). Improvements in liver function of symptomatic patients was similar between groups when data were stratified between first and second line treatments, with improvement rates during first line therapy in symptomatic patients of 90.7% for D-penicillamine and 92.6% for trientine.


Contact: Dimple Natali
European Association for the Study of the Liver

Related biology news :

1. UC Riverside researcher receives $9 million USDA grant to study potato and tomato disease
2. New study shows you can have your candy and eat it too -- without adverse health effects
3. Study: Emissions trading doesnt cause pollution hot spots
4. Butterfly study reveals traits and genes associated with establishment of new populations
5. Study shows hunger hitting closer to home
6. Most states unclear about storage, use of babies blood samples, new study finds
7. GPS study shows wolves more reliant on a cattle diet
8. Russian boreal forests undergoing vegetation change, study shows
9. Spicing up your love life possible, study finds
10. Study finds weight training safe for pregnant women
11. Study predicts large regional changes in farmland area
Post Your Comments:
(Date:10/13/2015)... 13, 2015 Feedzai , a data ... big data and minimize risk in the financial industry, ... an innovative fraud prevention solution that gives merchants the ... a user,s email address. The two companies will provide ... combines email risk assessment with fraud risk scoring to ...
(Date:10/13/2015)... Dragon Capital Group Corp. (OTC: DRGV), ... China , announced today that its wholly owned subsidiary, ... contract for Multi-Format Naked Eye 3D System for a period ... the project that is expected to be completed in 2015. ... gross profits. --> --> ...
(Date:10/13/2015)... Research and Markets ( ) has announced the ... Market - Estimation & Forecast (2015-2020)" report to ... --> The biometric market value is anticipated to ... in 2020 at an estimated CAGR of 16.47% from ... . Growing digitization in the government sector is expected ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... ... October 13, 2015 , ... AxioMx Inc. , a ... received a Phase I Small Business Innovative Research (SBIR) grant (1R43GM112204-01A1). This Phase ... Sciences (NIGMS), will fund the development of a technique to rapidly convert single-chain ...
(Date:10/13/2015)... N.J. and SAN DIEGO ... and Mast Therapeutics, Inc. have agreed to collaborate in ... excipient-grade poloxamer 188 NF, marketed by BASF under the ... in a variety of pharmaceutical and biological applications, such ... 188 is the starting material for Mast,s lead product ...
(Date:10/13/2015)... 13, 2015      Q BioMed ... has entered into a strategic relationship with Wombat Capital, ... Paris, France based strategic and ... --> This collaborative arrangement gives Q BioMed and ... team as well as long established pharmaceutical industry relationships. ...
(Date:10/13/2015)... 2015 TapImmune, Inc. (TPIV), ... innovative peptide and gene-based immunotherapeutics and vaccines for the ... featured presenting company at the Dawson James Small ... in Jupiter, Florida on October ... a clinical-stage immunotherapy company specializing in the development of ...
Breaking Biology Technology: